1．Mvunta DH, Miyamoto T, Asaka R, Yamada Y, Ando H, Higuchi S, Ida K, Kashima H,Shiozawa T.
Overexpression of SIRT1 is Associated With Poor Outcomes in Patients With Ovarian Carcinoma.
Immunohistochem Mol Morphol.25(6),415-421,2017
2．Ando H, Miyamoto T, Kashima H, Higuchi S, Ida K, Mvunta DH, Shiozawa T.
Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
Horm Cancer. 8(4)，257-267, 2017
3．Mvunta DH, Miyamoto T, Asaka R, Yamada Y, Ando H, Higuchi S, Ida K, Kashima H, Shiozawa T.
SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells.
Transl Oncol. 10(4)，621-631. 2017
4．Kobara H, Kashima H, Miyamoto T, Yamada Y, Asaka S, Shiozawa T.
A case of pure-type ovarian squamous cell carcinoma producing granulocyte-colony stimulating factor.
Gynecol Oncol Rep. 4，22:89-91. 2017
5． Asaka R, Miyamoto T, Yamada Y, Ando H, Mvunta DH, Kobara H, Kashima H, Shiozawa T.
Elevated Serum Levels of Estradiol Induce Endometrial Hyperplasia Rather than Carcinoma in a Mouse Model Using a Carcinogen.
J Carcinog Mutagen. 8(6)，1-6. 2017
6．Satoshi Ohira, Ryoichi Asaka, Yasuhiro Tanaka, Chiho Fuseya, Hirofumi Ando, Norihiko Kikuchi, Tsutomu Miyamoto, Makoto Kanai, Tanri Shiozawa.
Management of a pregnant woman with idiopathic interstitial pneumonia accompanied by secondary pulmonary hypertension: case report and literature review.
Med Case Rep．3(4)，46，2017
7．Kobayashi Y, Kashima H, Rahmanto YS, Banno K, Yu Y, Matoba Y, Watanabe K, Iijima M, Takeda T, Kunitomi H, Iida M, Adachi M, Nakamura K, Tsuji K, Masuda K, Nomura H, Tominaga E, Aoki D.
Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer.
Oncotarget 8(42)，72147-72156，2017
